Why the study?
Heart failure with preserved ejection fraction remains without evidence-based pharmacotherapy and carries high morbidity and mortality, driven by unclear etiological factors and heterogeneous phenotypes.
Answers are grounded in this paper and cite their sources.
HFpEF is a heterogeneous syndrome lacking evidence-based pharmacotherapy, requiring better phenotyping and potentially machine learning for future therapeutic strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Adamczak et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: